A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals
Open Access
- 3 December 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1450853
Abstract
Introduction: Long COVID is a debilitating condition that lasts for more than three months post-infection by SARS–CoV–2. On average, one in ten individuals infected with SARS CoV- 2 develops Long COVID worldwide. A knowledge gap exists in our understanding of the mechanisms, genetic risk factors, and biomarkers that could be associated with Long COVID.Methods: In this pilot study we used RNA-Seq to quantify the transcriptomes of peripheral blood mononuclear cells isolated from COVID-recovered individuals, seven with and seven without Long COVID symptoms (age- and sex-matched individuals), on average 6 months after infection.Results: Seventy genes were identified as significantly up- or down-regulated in Long COVID samples, and the vast majority were downregulated. The most significantly up- or downregulated genes fell into two main categories, either associated with cell survival or with inflammation. This included genes such as ICOS (FDR p = 0.024) and S1PR1 (FDR p = 0.019) that were both up-regulated, indicating that a pro-inflammatory state is sustained in Long COVID PBMCs compared with COVID recovered PBMCs. Functional enrichment analysis identified that immune-related functions were expectedly predominant among the up- or down-regulated genes. The most frequently downregulated genes in significantly altered functional categories were two leukocyte immunoglobulin like receptors LILRB1 (FDR p = 0.005) and LILRB2 (FDR p = 0.027). PCA analysis demonstrated that LILRB1 and LILRB2 expression discriminated all of the Long COVID samples from COVID recovered samples.Discussion: Downregulation of these inhibitory receptors similarly indicates a sustained pro-inflammatory state in Long COVID PBMCs. LILRB1 and LILRB2 should be validated as prospective biomarkers of Long COVID in larger cohorts, over time and against clinically overlapping conditions.Keywords
This publication has 49 references indexed in Scilit:
- Fibrinogen-like protein 2 in inflammatory diseases: A future therapeutic targetInternational Immunopharmacology, 2023
- Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic revieweClinicalMedicine, 2022
- Plasma biomarkers for systemic inflammation in COVID‐19 survivorsProteomics – Clinical Applications, 2022
- Sarcopenia as potential biological substrate of long COVID‐19 syndrome: prevalence, clinical features, and risk factorsJournal of Cachexia, Sarcopenia and Muscle, 2022
- Advances in understanding the specificity function of transporters by machine learningComputers in Biology and Medicine, 2021
- CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronavirusesImmunity, 2021
- Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort studyJournal of Infection, 2021
- Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE)Journal of Autoimmunity, 2007
- Induction, binding specificity and function of human ICOSEuropean Journal of Immunology, 2000
- The respiratory burst oxidase.Journal of Biological Chemistry, 1994